KR950703949A - 히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds) - Google Patents
히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds)Info
- Publication number
- KR950703949A KR950703949A KR1019950702199A KR19950702199A KR950703949A KR 950703949 A KR950703949 A KR 950703949A KR 1019950702199 A KR1019950702199 A KR 1019950702199A KR 19950702199 A KR19950702199 A KR 19950702199A KR 950703949 A KR950703949 A KR 950703949A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- compound
- hydrogen
- lower alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003963 antioxidant agent Substances 0.000 title abstract 3
- 230000003078 antioxidant effect Effects 0.000 title abstract 3
- QBPAUIDFWFXLKB-UHFFFAOYSA-N 9h-carbazol-1-ol Chemical class N1C2=CC=CC=C2C2=C1C(O)=CC=C2 QBPAUIDFWFXLKB-UHFFFAOYSA-N 0.000 title abstract 2
- 230000003293 cardioprotective effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 241000124008 Mammalia Species 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 208000014674 injury Diseases 0.000 claims abstract 3
- 230000000302 ischemic effect Effects 0.000 claims abstract 3
- 210000000056 organ Anatomy 0.000 claims abstract 3
- 230000001590 oxidative effect Effects 0.000 claims abstract 3
- 230000000451 tissue damage Effects 0.000 claims abstract 3
- 231100000827 tissue damage Toxicity 0.000 claims abstract 3
- 230000008733 trauma Effects 0.000 claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 230000004224 protection Effects 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 230000000747 cardiac effect Effects 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003435 aroyl group Chemical group 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 3
- -1 methylenedioxy Chemical group 0.000 claims 3
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000001631 hypertensive effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000004792 oxidative damage Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000005961 cardioprotection Effects 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paper (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98391692A | 1992-12-01 | 1992-12-01 | |
| US07/983916 | 1992-12-01 | ||
| PCT/US1993/011597 WO1994012177A1 (en) | 1992-12-01 | 1993-12-01 | Antioxydant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950703949A true KR950703949A (ko) | 1995-11-17 |
Family
ID=25530177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950702199A Ceased KR950703949A (ko) | 1992-12-01 | 1993-12-01 | 히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5405863A (enExample) |
| EP (1) | EP0671913A1 (enExample) |
| JP (1) | JPH08503710A (enExample) |
| KR (1) | KR950703949A (enExample) |
| CN (1) | CN1043509C (enExample) |
| AU (1) | AU675481B2 (enExample) |
| CA (1) | CA2150694A1 (enExample) |
| WO (1) | WO1994012177A1 (enExample) |
| ZA (1) | ZA938896B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000510110A (ja) * | 1996-04-29 | 2000-08-08 | スミスクライン・ビーチャム・コーポレイション | 抗酸化化合物 |
| WO1998015272A1 (en) | 1996-10-09 | 1998-04-16 | BOEHRINGER MANNHEIM PHARMACEUTICALS CORP. - SMITHKLINE BEECHAM CORPORATION, LIMITED PARTNERSHIP No.1 | Method for inhibiting stress-activated protein kinases |
| JP4126345B2 (ja) * | 1997-03-06 | 2008-07-30 | 松森 昭 | ウイルス感染症の予防・治療剤 |
| US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
| AU5251999A (en) | 1998-08-04 | 2000-02-28 | Wisconsin Alumni Research Foundation | Method of reducing retinal ganglion cell degeneration |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US20050148779A1 (en) * | 2002-04-30 | 2005-07-07 | Wei Chen | Carvedilol monocitrate monohydrate |
| US20050261355A1 (en) * | 2002-06-27 | 2005-11-24 | Sb Pharmco Puerto Rico Inc., | Carvedilol hydobromide |
| KR101468827B1 (ko) * | 2002-06-27 | 2014-12-03 | 스미스클라인 비이참 (코르크) 리미티드 | 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법 |
| US20050020666A1 (en) * | 2003-07-25 | 2005-01-27 | Dabur Research Foundation | Cardioprotective agents |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| EP1691789B1 (en) * | 2003-11-25 | 2017-12-20 | SmithKline Beecham (Cork) Limited | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| EP1686986A4 (en) * | 2003-11-25 | 2009-05-27 | Sb Pharmco Inc | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT |
| US20090076116A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched carvediolo |
| US10281374B2 (en) * | 2015-11-04 | 2019-05-07 | Diagnostic Biosystems | Method of pretreatment of biological samples for an analyte-staining assay method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4438559A (en) * | 1980-06-27 | 1984-03-27 | Fuji Machine Mfg. Co. Ltd. | Apparatus for automatically mounting non-lead electronic components on printed-circuit |
-
1993
- 1993-09-28 US US08/128,327 patent/US5405863A/en not_active Expired - Lifetime
- 1993-11-29 ZA ZA938896A patent/ZA938896B/xx unknown
- 1993-12-01 WO PCT/US1993/011597 patent/WO1994012177A1/en not_active Ceased
- 1993-12-01 CA CA002150694A patent/CA2150694A1/en not_active Abandoned
- 1993-12-01 JP JP6513450A patent/JPH08503710A/ja active Pending
- 1993-12-01 CN CN93120407A patent/CN1043509C/zh not_active Expired - Fee Related
- 1993-12-01 EP EP94903350A patent/EP0671913A1/en not_active Ceased
- 1993-12-01 KR KR1019950702199A patent/KR950703949A/ko not_active Ceased
- 1993-12-01 AU AU57322/94A patent/AU675481B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US5405863A (en) | 1995-04-11 |
| CN1098909A (zh) | 1995-02-22 |
| WO1994012177A1 (en) | 1994-06-09 |
| CN1043509C (zh) | 1999-06-02 |
| AU675481B2 (en) | 1997-02-06 |
| ZA938896B (en) | 1994-08-01 |
| JPH08503710A (ja) | 1996-04-23 |
| AU5732294A (en) | 1994-06-22 |
| CA2150694A1 (en) | 1994-06-09 |
| EP0671913A1 (en) | 1995-09-20 |
| EP0671913A4 (enExample) | 1995-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950703949A (ko) | 히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds) | |
| KR890011592A (ko) | 기관내 허혈병의 치료용 조성물 | |
| DE69630479T2 (de) | Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten | |
| KR920700200A (ko) | 19-노르-비타민 d 화합물 | |
| RU97115713A (ru) | Соединения, содержащие бензопиран и способ их применения | |
| US6156799A (en) | Method of increasing bone volume using non-naturally-occurring FP selective agonists | |
| KR890003369A (ko) | 약제학적 제제 | |
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| CA2310534A1 (en) | Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) | |
| KR910016931A (ko) | 과콜레스테린혈증 치료제 | |
| KR880006193A (ko) | 피페리딘 화합물 및 그의 제조 및 용도 | |
| BG99164A (bg) | Антиисхемично лекарствено средство | |
| JP2004502732A5 (enExample) | ||
| RU2097040C1 (ru) | Применение креатинфосфата для лечения опухолей и фармацевтические препараты, обладающие противоопухолевой активностью | |
| US4513007A (en) | Method for treating heart disease | |
| GB2178314A (en) | Pharmaceutical compositions containing ubiquinone coenzymes | |
| KR950703950A (ko) | 히드록시카르바졸 화합물의 항산화성 신경보호 용도 및 이를 이용한 치료 방법(Antioxidant Neuroprotective Use of, and Method of Treatment Using, Hydroxycarbazole Compounds) | |
| US20050282769A1 (en) | Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| JP2001527510A (ja) | カルシウムチャンネル拮抗物質としての三環式ピロリジン誘導体 | |
| KR970064604A (ko) | 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도 | |
| KR960700711A (ko) | 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) | |
| US6340693B1 (en) | Protective agent for nervous system structural cells | |
| KR900000383A (ko) | 신규 화합물 | |
| KR970061887A (ko) | 치환된 티오페닐알케닐카복실산 구아니디드, 이의 제조방법, 약물 및 진단제로서의 이의 용도 및 이를 함유하는 약제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19950531 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19981130 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000630 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20010430 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20000630 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20010602 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20010430 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20021125 Appeal identifier: 2001101001521 Request date: 20010602 |
|
| J801 | Dismissal of trial |
Free format text: REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010602 Effective date: 20021125 |
|
| PJ0801 | Rejection of trial |
Decision date: 20021125 Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2001101001521 Request date: 20010602 |